Spots Global Cancer Trial Database for neurofibroma, plexiform
Every month we try and update this database with for neurofibroma, plexiform cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Real-World Treatment Study of Koselugo (Selumetinib) | NCT06360406 | Neurofibromatos... Neurofibroma, P... | 3 Years - 18 Years | AstraZeneca | ||
| Study of Imatinib in Children With Neurofibromatosis and Airway Tumors | NCT03688568 | Neurofibroma, P... | Imatinib Mesyla... | 6 Months - 12 Years | Indiana University | |
| Treatment of NF1-related Plexiform Neurofibroma With Trametinib | NCT03741101 | Neurofibromatos... Child Neurofibroma, P... | Trametinib | 1 Year - 17 Years | Region Skane | |
| Study of Imatinib in Children With Neurofibromatosis and Airway Tumors | NCT03688568 | Neurofibroma, P... | Imatinib Mesyla... | 6 Months - 12 Years | Indiana University | |
| Evaluation of Percutaneous Cryotherapy in the Treatment of Plexiform Neurofibromas and Unresectable Neurofibromas in Neurofibromatosis Type 1 | NCT05199376 | Neurofibroma Neurofibroma, P... | Cryotherapy | 18 Years - | Centre Leon Berard | |
| Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas | NCT03231306 | Neurofibromatos... Plexiform Neuro... | Binimetinib | 1 Year - | University of Alabama at Birmingham | |
| Treatment of NF1-related Plexiform Neurofibroma With Trametinib | NCT03741101 | Neurofibromatos... Child Neurofibroma, P... | Trametinib | 1 Year - 17 Years | Region Skane | |
| Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics | NCT03027401 | Neoplasms Adenomatous Pol... Neurofibroma, P... Myelodysplastic... | - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics | NCT03027401 | Neoplasms Adenomatous Pol... Neurofibroma, P... Myelodysplastic... | - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics | NCT03027401 | Neoplasms Adenomatous Pol... Neurofibroma, P... Myelodysplastic... | - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| Treatment of NF1-related Plexiform Neurofibroma With Trametinib | NCT03741101 | Neurofibromatos... Child Neurofibroma, P... | Trametinib | 1 Year - 17 Years | Region Skane | |
| Study of Imatinib in Children With Neurofibromatosis and Airway Tumors | NCT03688568 | Neurofibroma, P... | Imatinib Mesyla... | 6 Months - 12 Years | Indiana University | |
| R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas | NCT00021541 | Neurofibroma, P... Neurofibromatos... | tipifarnib placebo | 3 Years - 25 Years | National Institutes of Health Clinical Center (CC) | |
| AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors | NCT01362803 | Neurofibromatos... Neurofibromatos... NF1 Neurofibroma, P... | AZD6244 | 2 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors | NCT01362803 | Neurofibromatos... Neurofibromatos... NF1 Neurofibroma, P... | AZD6244 | 2 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| Real-World Treatment Study of Koselugo (Selumetinib) | NCT06360406 | Neurofibromatos... Neurofibroma, P... | 3 Years - 18 Years | AstraZeneca | ||
| Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas | NCT03231306 | Neurofibromatos... Plexiform Neuro... | Binimetinib | 1 Year - | University of Alabama at Birmingham | |
| Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNs | NCT06175637 | Neurofibroma, P... | 3 Years - 16 Years | AstraZeneca | ||
| Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ... | NCT02390752 | Neurofibroma, P... Precursor Cell ... Leukemia, Promy... Sarcoma | TURALIO(R) | 3 Years - 35 Years | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
